Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination
出版年份 2015 全文链接
标题
Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination
作者
关键词
-
出版物
OncoImmunology
Volume 5, Issue 1, Pages e1057673
出版商
Informa UK Limited
发表日期
2015-06-06
DOI
10.1080/2162402x.2015.1057673
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
- (2012) K. P. Wevers et al. ANNALS OF SURGICAL ONCOLOGY
- Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma
- (2012) E. H. J. G. Aarntzen et al. CANCER RESEARCH
- Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination
- (2012) E. H. J. G. Aarntzen et al. CANCER RESEARCH
- Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
- (2012) E. H. J. G. Aarntzen et al. CLINICAL CANCER RESEARCH
- Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial
- (2012) Bryan H Burmeister et al. LANCET ONCOLOGY
- Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients
- (2011) W. J. Lesterhuis et al. CLINICAL CANCER RESEARCH
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
- (2010) W. Joost Lesterhuis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
- (2010) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma
- (2009) Shefali Agrawal et al. CANCER
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Spontaneous regression of metastases from melanoma: review of the literature
- (2009) Louise Vennegaard Kalialis et al. MELANOMA RESEARCH
- Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells
- (2008) Danita H. Schuurhuis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Melanoma epidemiology and trends
- (2008) Claus Garbe et al. CLINICS IN DERMATOLOGY
- Dendritic cell vaccines in melanoma: From promise to proof?
- (2008) W.J. Lesterhuis et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now